Search results
Results from the WOW.Com Content Network
Bromazolam (XLI-268) is a triazolobenzodiazepine (TBZD) which was first synthesised in 1976, but was never marketed. [2] It has subsequently been sold as a designer drug, first being definitively identified by the EMCDDA in Sweden in 2016. [3]
The tables below contain a sample list of benzodiazepines and benzodiazepine analogs that are commonly prescribed, with their basic pharmacological characteristics, such as half-life and equivalent doses to other benzodiazepines, also listed, along with their trade names and primary uses.
Flubromazolam (JYI-73) [2] [3] [4] is a triazolobenzodiazepine (TBZD), which are benzodiazepine (BZD) derivatives. [5] [6] [7] [8] [9] [10] [11] Flubromazolam is ...
Phenazepam (also known in Russia as bromdihydrochlorphenylbenzodiazepine) is a benzodiazepine drug, first developed in the Soviet Union in 1975, [7] and now produced ...
Pyrazolam (SH-I-04) [2] is a benzodiazepine derivative originally developed by a team led by Leo Sternbach at Hoffman-La Roche in the 1970s. [3] It has since been "rediscovered" and sold as a designer drug since 2012.
Gidazepam acts as a prodrug to its active metabolite 7-bromo-2,3-dihydro-5-phenyl-1H-1,4-benzodiazepin-2-one (desalkylgidazepam or bromo-nordazepam). [11] [12] Its anxiolytic effects can take several hours to manifest presumably due to its slow metabolism (half-life 87 hours). The onset and intensity of anxiolytic effects correlate with blood ...
The drug policy of Romania changed significantly in 2014 when penalties for a range of drug related offences were reduced. Drug use was not decriminalized but it became possible to avoid a jail sentence.
Rilmazafone [1] (リスミー, Rhythmy, previously known as 450191-S) is a water-soluble prodrug developed in Japan. [2] Inside the human body, rilmazafone is converted into several benzodiazepine metabolites that have sedative and hypnotic effects.